{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-clear+Cell+Renal+Cell+Carcinoma&page=5", "query": { "condition": "Advanced Non-clear Cell Renal Cell Carcinoma", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 161, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-clear+Cell+Renal+Cell+Carcinoma&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-clear+Cell+Renal+Cell+Carcinoma&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T10:00:41.408Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01005797", "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cancer", "Non Small Cell Lung Cancer (NSCLC)", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Panobinostat (LBH589), Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2009-11", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005797" }, { "nct_id": "NCT02262455", "title": "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "Solid Tumors" ], "interventions": [ { "name": "STM 434", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santa Maria Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2014-10", "completion_date": "2017-01-13", "has_results": false, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02262455" }, { "nct_id": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma", "Nasopharyngeal Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer" ], "interventions": [ { "name": "P-MUC1C-ALLO1 CAR-T cells", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2022-02-15", "completion_date": "2039-04", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 14, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 11 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239143" }, { "nct_id": "NCT05721222", "title": "Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "GEN1160", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2023-03-15", "completion_date": "2025-11-05", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Ann Arbor, Michigan + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05721222" }, { "nct_id": "NCT00491075", "title": "Pemetrexed Plus Gemcitabine in Renal Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 16, "start_date": "2005-12", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-04-24", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00491075" }, { "nct_id": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology", "Solid Tumor", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Melanoma", "Bladder Cancer" ], "interventions": [ { "name": "MRx0518", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "4D pharma plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2019-01-10", "completion_date": "2023-05-08", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 5, "location_summary": "Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637803" }, { "nct_id": "NCT06332755", "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer(NSCLC)", "Head and Neck Squamous Cell Carcinoma(HNSCC)", "Renal Cell Carcinoma(RCC)", "Urothelial Carcinoma", "Malignant Melanoma" ], "interventions": [ { "name": "Phase 1a: LB-LR1109", "type": "DRUG" }, { "name": "Phase 1b: LB-LR1109 and Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LG Chem", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2024-06-05", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06332755" }, { "nct_id": "NCT04353765", "title": "Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Locally Advanced or Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib monotherapy", "type": "DRUG" }, { "name": "All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2020-01-30", "completion_date": "2020-06-05", "has_results": false, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 1, "location_summary": "The Woodlands, Texas", "locations": [ { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04353765" }, { "nct_id": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Differentiated Thyroid Gland Carcinoma", "Advanced Head and Neck Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Kaposi Sarcoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Prostate Carcinoma", "Advanced Renal Cell Carcinoma", "Advanced Thyroid Gland Medullary Carcinoma", "Advanced Triple-Negative Breast Carcinoma", "Advanced Urothelial Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "HIV Infection", "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic Head and Neck Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Kaposi Sarcoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Thyroid Gland Medullary Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Kaposi Sarcoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Medullary Carcinoma", "Recurrent Triple-Negative Breast Carcinoma", "Recurrent Urothelial Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2021-11-22", "completion_date": "2027-02-06", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 3, "location_summary": "Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514484" }, { "nct_id": "NCT02697591", "title": "A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2016-06-20", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-02-26", "last_synced_at": "2026-10-11T10:00:41.408Z", "location_count": 8, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Middletown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02697591" } ] }